Abbvie Inc.

Abbvie Deutschland Gmbh and Co Kg

Abbott Gmbh & Co Kg

Claudia Packhaeuser

Bernd Liepold

Thomas Kessler

Joerg Breitenbach

Drazen Kostelac

Martin Knobloch

Markus Maegerlein

Norbert Steiger

The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders.

Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor

Growing community of inventors

Mannheim, Germany

Claudia Packhaeuser